Evista (raloxifene), the new designer estrogen

January 1998

    You're going to hear a lot about Evista (raloxifene), the new "designer estrogen" from Lilly.

    It's INITIALLY approved just to prevent osteoporosis.

    But Evista and future designer estrogens will revolutionize hormone replacement therapy because they're more selective. They mimic the effects of estrogen in SOME tissues...but not others.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote